Zacks has a useful updated analysis of IMNP's development of bertilimumab. IMNP just received a decent chunk of funding that will take them well into 2017. ICO, of course, licenses bertilimumab to IMNP and will receive milestone payments if b-mab progresses. Yahoo is not letting me link. Take a look at @ZacksSmallCap on Twitter to find the link.
Bertilimumab and IMNP given a nice analysis by David Bautz of Zacks. FWIW, he thinks bertilimumab has "blockbuster" potential. http://seekingalpha.com/article/3293955-an-overview-of-immune-pharmaceuticals-as-bertilimumab-enters-the-clinic
IMNP partnership discussions progressing (gentle way of saying they are not going to make the "end of Q2" prediction they made. They should have just said, "mid-year." http://finance.yahoo.com/news/immune-pharmaceuticals-signs-license-research-120000730.html